STAT

JULY 30, 2024

A new study suggests that an older GLP-1 drug may help protect the brains of people with early Alzheimer’s disease, supporting the case for further research on the class of medications — originally developed for obesity and diabetes — in neurological diseases.

Diabetes 351

Diabetes 351

STAT

SEPTEMBER 10, 2024

weight loss, according to an abstract of data that will be presented Wednesday at the annual meeting of the European Association for the Study of Diabetes. Participants who took two pills a day had 13.1% weight loss. Meanwhile, those on placebo experienced 1.1%

Diabetes 316

Diabetes 316

Express Pharma

MARCH 13, 2025

A recent study published in Springer Medizin has identified insulinoma-associated protein 2 autoantibody (IA-2A) positivity as a significant biomarker for disease progression in individuals at risk of type 1 diabetes (T1D). per cent, increasing from $2.2 billion in 2023 to $9.9 per cent, increasing from $2.2 billion in 2023 to $9.9

Diabetes 66

Diabetes Compounding 66

STAT

MARCH 7, 2024

weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. The drug is also sold as a diabetes treatment under the name Ozempic. In a Phase 1 trial, participants experienced an average of 13.1% billion in sales last year.

Diabetes 313

Diabetes 313

STAT

DECEMBER 6, 2023

In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. The news about anti-obesity drugs keeps getting better. That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering.

Diabetes 269

Diabetes Drug Pricing 269

STAT

JUNE 23, 2023

The full   results,  published Friday in the New England Journal of Medicine, were presented here to a packed conference room at the American Diabetes Association conference. The mid-stage results for orforglipron match the estimates of 14-15% weight loss that Lilly gave in an investor call late last year.

Diabetes 249

Diabetes Drug Development 249

STAT

MAY 29, 2024

  EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. The companies did not immediately comment.  

Diabetes 252

Diabetes 252

pharmaphorum

AUGUST 24, 2021

million in first-round financing, which it will use to scale up its clinical tool that it says helps people “prevent, manage and reverse type 2 diabetes.” It also sets competitive challenges to improve behaviours, provides a forum to interact with other people with diabetes, and access to a personal coach.

Diabetes 126

Diabetes 126

STAT

JUNE 26, 2023

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Diabetes 245

Diabetes Drug Development 245

STAT

FEBRUARY 8, 2024

On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.  

Drug Pricing 265

Drug Pricing Diabetes 265

European Pharmaceutical Review

OCTOBER 18, 2023

TZIELD (teplizumab-mzwv) has demonstrated TZIELD’s potential to slow disease progression in newly diagnosed children and adolescents with Stage 3 type 1 diabetes. Data from the Phase III PROTECT clinical trial , presented at the 2023 Annual ISPAD Conference, showed that superior beta cell preservation was observed compared to placebo.

Diabetes 111

Diabetes 111

STAT

DECEMBER 12, 2023

So join us as we hoist the ever-present cup of stimulation — our choice today is gingerbread — and attack the fast-growing to-do list. People who discontinue Wegovy and Novo Nordisk’s diabetes medication Ozempic have also regained weight, raising concerns among U.S. We trust you have your own hectic agendas.

Diabetes 230

Diabetes 230

Pharmaceutical Technology

OCTOBER 7, 2022

Provention Bio and Sanofi US have signed a co-promotion agreement to launch the former’s lead investigational drug candidate, teplizumab for the delay in the onset of clinical type 1 diabetes (T1D). The US Food and Drug Administration (FDA) is presently reviewing teplizumab for the delay of clinical T1D in people who are at risk.

Diabetes 119

Diabetes 119

Express Pharma

MAY 17, 2024

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of incretin mimetic medicines for the treatment of type 2 diabetes and obesity. With the obesity and type 2 diabetes markets growing at unprecedented rates, the GLP-1 receptor agonists market is also growing. per cent and 0.57

Diabetes 111

Diabetes 111

STAT

APRIL 4, 2024

Meanwhile, we are proud to present our latest list of interesting items for you to peruse. A drugmaker in China has developed a biosimilar version of Novo Nordisk’s popular diabetes drug Ozempic and applied for approval to sell it there, in a potential challenge to Novo expansion plans in the country , Reuters writes.

Diabetes 230

Diabetes Biosimilars 230

Express Pharma

JUNE 28, 2023

The data was highlighted in poster presentations at the American Diabetes Association’s (ADA) 83rd Scientific Sessions held from June 23-26, 2023, in San Diego, CA. The data was highlighted in poster presentations at the American Diabetes Association’s (ADA) 83rd Scientific Sessions held from June 23-26, 2023, in San Diego, CA.

Diabetes 98

Diabetes 98

Express Pharma

DECEMBER 2, 2024

This alarming trend presents a lucrative opportunity for drugmakers. The company’s Phase III product Rybelsus, already FDA approved for cardiovascular risk factors and type 2 diabetes, is being positioned for a label expansion to include obesity. The success of GLP-1R-targeting drugs highlights their viability as a treatment approach.

Labelling 126

Labelling Diabetes Drug Development 126

ALiEM - Pharm Pearls

OCTOBER 20, 2023

A 50-year-old Caucasian female with a history of hypertension, coronary artery disease, and insulin-dependent diabetes mellitus presents to the emergency department with a complaint of painful sores on the top of her left foot. It may be equally common in patients without diabetes, hence was renamed without the term “diabeticorum”.

Diabetes 161

Diabetes 161

Pharmafile

APRIL 1, 2025

Rybelsus (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).

Diabetes 59

Diabetes 59

Express Pharma

AUGUST 28, 2023

Queen’s University Belfast has designed a new 3D printed bandage which presents an innovative method of treatment to heal diabetic foot ulcers (DFUs). These scaffolds can release both a bulk and sustained release of antibiotic loaded molecules to treat diabetic ulcers.

Diabetes 98

Diabetes Dosage Compounding Hospitals 98

STAT

JUNE 27, 2023

The agreement was disclosed in a consent decree in which Lilly is prevented from rejecting applicants for primary care sales positions in its diabetes and obesity business units based on age. The arrangement will last for 30 months, according to the consent decree filed in a U.S. court in Indianapolis.

Diabetes 199

Diabetes 199

Pharma Mirror

SEPTEMBER 27, 2021

The post Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin appeared first on Pharma Mirror Magazine. The DREAM study is an observational, non-pharmacologic and non-interventional clinical study initiated by certain researchers participating in the.

Diabetes 52

Diabetes Hospitals 52

Pharmaceutical Technology

JANUARY 10, 2023

On November 17, 2022, the FDA approved Provention Bio’s Tzield (teplizumab) , making it the first and only treatment to delay the onset of type 1 diabetes (T1D). Tzield’s approval brings the opportunity to explore how the drug can advance diabetes education, treatment, and management. “We Equity in early-stage testing.

Diabetes 98

Diabetes Immunity Immunization Communication 98

ALiEM - Pharm Pearls

SEPTEMBER 20, 2024

A 50-year-old male with insulin-dependent Type 2 Diabetes presented to the emergency department with three days of pain and swelling on the right side of his neck. Patients may present with trismus, dysphagia, and fever. Additional Images Physical Exam Vitals : BP 153/96; HR 110; T 100.0°F;

Diabetes 177

Diabetes 177

ALiEM - Pharm Pearls

SEPTEMBER 15, 2023

A 64-year-old Caucasian male with a history of alcohol use disorder and tobacco use disorder presents with painless bilateral hand contractures that have been worsening for the past several months. Dupuytren’s Contracture is a clinical diagnosis that most commonly presents as painless loss of extension of the fourth and fifth phalanx.

Diabetes 152

Diabetes Clinic Management 152

STAT

JULY 26, 2023

So join us as we hoist the ever-present cup of stimulation and attack the to-do list. Shortages of an Eli Lilly diabetes drug, Mounjaro, have expanded to include all of the higher doses, showing just how strong demand is for the drug before it even gets formal approval for use in obesity , Bloomberg News notes.

Diabetes 208

Diabetes 208

Express Pharma

APRIL 25, 2023

Novo Nordisk collaborated with United Diabetes Forum (UDF) and Harley Owners Group to orchestrate a 90-minute ride from Bandra to Worli in Mumbai. In India, an estimated 135 million people live with Obesity which is almost double the number of people living with diabetes at present.

Diabetes 69

Diabetes 69

Pharmaceutical Technology

APRIL 16, 2024

NNC0519-0130 is commercialized by Novo Nordisk, with a leading Phase II program in Type 2 Diabetes.

Diabetes 75

Diabetes 75

Pharmaceutical Technology

JULY 1, 2024

RL-007 is a small molecule commercialized by Atai Life Sciences, with a leading Phase II program in Diabetic Neuropathic Pain.

Diabetes 75

Diabetes 75

Express Pharma

AUGUST 4, 2023

The pharma sector continues to present significant growth opportunities globally. Targeted therapies, precision medicine, and personalised treatments are gaining prominence, presenting opportunities for pharma companies to develop novel and more effective drugs. How is Novo Nordisk poised to leverage them?

Diabetes 98

Diabetes Communication 98

ALiEM - Pharm Pearls

SEPTEMBER 1, 2023

A 65-year-old male presented with chest and abdominal pain for three weeks. The most common pathogen is Klebsiella pneumoniae, and diabetes mellitus is the most common risk factor. Consider it especially in the patient with abdominal pain with diabetes mellitus. mmol/L; Glucose 538 mg/dL CRP : 42.6 mg/dL Ketone body : 5.9

Diabetes 161

Diabetes Hospitals 161

ALiEM - Pharm Pearls

AUGUST 18, 2023

A middle-aged man with a past medical history of hypertension and tobacco use disorder presented to the Emergency Department after evaluation by an ophthalmologist. On exam, complete CN III palsies will present with ipsilateral ptosis, “down and out” ocular deviation, and pupillary dilation.

Communication 130

Communication Diabetes 130

ALiEM - Pharm Pearls

SEPTEMBER 9, 2024

A 61-year-old female with a past medical history of hypertension, hyperlipidemia, type 2 diabetes, and normal pressure hydrocephalus s/p VP shunt (last revision nine months ago) presented to the Emergency Department (ED) for evaluation after noticing a “string” coming out of her anus today. Abdomen : Soft, nontender, nondistended.

Diabetes 152

Diabetes Hospitals 152

European Pharmaceutical Review

FEBRUARY 6, 2025

The US Food and Drug Administration (FDA) has approved Genentechs Susvimo (ranibizumab injection) 100 mg/mL as the first treatment for diabetic macular oedema (DME) via continuous delivery. Susvimo demonstrated sustained vision improvements in diabetic macular oedema. letters, respectively).

Diabetes 52

Diabetes 52

Pharmacy Times

JUNE 21, 2024

Presenters at the American Diabetes Association 84th Scientific Sessions, analyzed potential developments in treatment for patients with diabetes and diabetic kidney disease.

Diabetes 44

Diabetes 44

pharmaphorum

OCTOBER 29, 2014

Non-adherence to self-management regimens in diabetes is globally a widespread, costly and ultimately life threatening issue. The 15 minute presentation and 40 minute panel discussion will consider patient insights from our recent 'managing diabetes in the real world' tweetchat.

Diabetes 52

Diabetes 52

LifeProNow

APRIL 21, 2023

April 17, 2023 : “Bayer and its collaborator Regeneron will present new clinical data analyses for the investigational formulation aflibercept 8 mg at the Annual Meeting of The Association for Research in Vision and Ophthalmology (arvo.org) 2023 , in New Orleans, Louisiana, 23-27 April 2023.

Diabetes 100

Diabetes 100